Skip to main content
NCBI home page
UKPMC Funders Author Manuscripts logoLink to UKPMC Funders Author Manuscripts
. Author manuscript; available in PMC: 2016 May 1.
Published in final edited form as: Leukemia. 2015 Jun 9;29(11):2230–2237. doi: 10.1038/leu.2015.138

Identification of bromodomain-containing protein 4 (BRD4) as a novel marker and epigenetic target in mast cell leukemia

Ghaith Wedeh 1,2, Sabine Cerny-Reiterer 1,3, Gregor Eisenwort 1,3, Harald Herrmann 3,4, Katharina Blatt 1, Emir Hadzijusufovic 1,3, Irina Sadovnik 1, Leonhard Müllauer 5, Juliana Schwaab 6, Thomas Hoffmann 7, James E Bradner 8, Deepti Radia 9, Wolfgang R Sperr 1,3, Gregor Hoermann 10, Andreas Reiter 6, Hans-Peter Horny 11, Johannes Zuber 7, Michel Arock 2, Peter Valent 1,3,*
PMCID: PMC4610040  EMSID: EMS63111  PMID: 26055303

Abstract

Advanced systemic mastocytosis (SM) is a life-threatening neoplasm characterized by uncontrolled growth and accumulation of neoplastic mast cells (MCs) in various organs and a poor survival. So far, no curative treatment concept has been developed for these patients. We identified the epigenetic reader bromodomain-containing protein-4 (BRD4) as novel drug target in aggressive SM (ASM) and MC leukemia (MCL). As assessed by immunohistochemistry and PCR, neoplastic MCs expressed substantial amounts of BRD4 in ASM and MCL. The human MCL lines HMC-1 and ROSA also expressed BRD4, and their proliferation was blocked by a BRD4-specific shRNA. Correspondingly, the BRD4-targeting drug JQ1 induced dose-dependent growth inhibition and apoptosis in HMC-1 cells and ROSA cells, regardless of the presence or absence of KIT D816V. In addition, JQ1 suppressed the proliferation of primary neoplastic MCs obtained from patients with ASM or MCL (IC50: 100-500 nM). In drug combination experiments, midostaurin (PKC412) and all-trans retinoic acid (ATRA) were found to cooperate with JQ1 in producing synergistic effects on survival in HMC-1 and ROSA cells. Together, we have identified BRD4 as a promising drug target in advanced SM. Whether JQ1 or other BET-bromodomain inhibitors are effective in vivo in patients with advanced SM remains to be elucidated.

Keywords: Mast cell leukemia, KIT, BRD4, bromodomain inhibitors, JQ1

Introduction

Systemic mastocytosis (SM) is a hematopoietic stem cell disorder characterized by pathologic expansion and accumulation of clonal mast cells (MCs) in one or more internal organs.1-5 Indolent and advanced types of the disease have been described.1-5 The classification of the World Health Organization (WHO) delineates 4 major categories of SM, namely indolent SM (ISM), SM with an associated clonal hematopoietic non-MC-lineage disease (SM-AHNMD), aggressive SM (ASM) and MC leukemia (MCL).6-8 The smoldering subtype of SM (SSM), initially considered a subtype of ISM, is now also regarded a separate SM category.9 In ISM, the prognosis is quite favorable. In fact, despite mediator-related symptoms, cosmetic problems and the neoplastic nature of the disease, patients with ISM have a normal or near-normal life expectancy.5-8 By contrast, in patients with advanced SM (ASM, SM-AHNMD, MCL) the prognosis is grave.6-8,10-15 In these patients, cytoreductive therapy is administered to suppress MC expansion in various organ-systems.9,10,12-16 However, unfortunately, clonal MCs in these patients are often resistant against anti-cancer drugs. Therefore, research efforts focus on new potential drug targets in neoplastic MCs and the development of novel targeted drugs for advanced SM.16-18

One potential drug target in ASM and MCL is KIT D816V, a SM-related oncoprotein.17,18 This transforming mutant is detectable in a majority of all patients with SM, including ASM and MCL.19-21 KIT D816V is expressed in MCs as well as in MC progenitors in these patients, and is considered to contribute substantially to differentiation and survival of neoplastic MCs.21-23 However, so far, only a few tyrosine kinase inhibitors (TKIs) were found to counteract the growth and survival of KIT D816V+ neoplastic MCs in patients with advanced SM.18,24-27 One of the most encouraging agents is the multi-kinase inhibitor PKC412, also known as midostaurin. However, despite impressive efficacy, responses to PKC412 in ASM and MCL are often incomplete or short-lived.27,28 Therefore, research is seeking additional drug targets expressed by neoplastic MCs.

During the past few years, chromatin-regulatory molecules and related antigens have been examined as potential therapeutic targets in diverse human malignancies.29-31 One promising class of targets is the bromodomain-containing proteins.30-32 In order to identify candidate therapeutic targets in the chromatin regulatory network in acute myeloid leukemia (AML) we have recently performed a multiplexed shRNA screen in a genetically engineered mouse model of AML.32 In this screen, we identified the ‘epigenetic reader’ bromodomain-containing 4 protein (BRD4) as a promising new target in AML.32 Thus, inhibition of BRD4 by exposure to RNAi or treatment with JQ1, a drug blocking the specific interactions between BRD4 and acetylated histones, resulted in major anti-leukemic effects in murine and human AML cells.32,33

The aims of the present study were to explore whether neoplastic MCs in MCL and other types of SM express BRD4 and whether BRD4 serves as a druggable target in these incurable malignancies.

Patients and Methods

Reagents

A description of reagents is provided in the Supplementary Materials. A specification of monoclonal antibodies (mAb) used is shown in Supplementary Table S1.

Patients and isolation of primary neoplastic MCs

Diagnostic bone marrow (BM) samples were obtained from the iliac crest of 62 patients with SM, including 46 with ISM (including one with SSM), 8 with ASM, 5 with SM-AHNMD, and 3 with MCL. Diagnoses were established according to WHO criteria.6-8 Patients’ characteristics are shown in Supplementary Table S2. BM aspirates were collected in syringes containing preservative-free heparin. All patients gave written informed consent before BM examination. The study was approved by the ethics committee of the Medical University of Vienna. Aspirated BM cells were layered over Ficoll to isolate mononuclear cells (MNCs). MNCs were examined for drug responses, expression of BRD4 mRNA, and presence of KIT mutations at codon 816 as reported.21,34 In one patient with MCL, a KIT D816H mutation was found. In most other patients, neoplastic cells were found to carry KIT D816V (Supplementary Table S2). Control samples (normal/reactive BM) were from patients with idiopathic cytopenia (n=2), lymphomas without BM infiltration (n=6), auto-immune thyroiditis (n=1), and chronic myeloid leukemia (CML) in major molecular response (n=1).

Cell lines

The MCL cell line HMC-1 35 was kindly provided by Dr.J.H.Butterfield (Mayo Clinic, Rochester, MN). Two sub-clones were used, HMC-1.1 expressing KIT V560G, and HMC-1.2 harboring KIT V560G and KIT D816V.24,36 HMC-1 cells were maintained in IMDM containing 10% FCS, L-glutamine and antibiotics (37°C, 5% CO2). The recently established human MC lines ROSAKIT WT and ROSAKIT D816V were cultured in IMDM with 10% FCS.37 ROSAKIT WT cells were maintained in stem cell factor (SCF), and ROSAKIT D816V cells without SCF. Chinese hamster ovary (CHO) cells transfected with the murine SCF gene served as a source of SCF.37 In select experiments, rhSCF was used. The identity of the HMC-1 and ROSA cell lines was confirmed by mutation analysis and phenotyping. For knock-down experiments, pRRL-SFFV-GFP-mir-E was constructed based on pRRL-SGEP38 by removing the PGK-Puro cassette. Knockdown-validated shRNAs targeting BRD4 or Renilla luciferase (Supplementary Table S3) were cloned using XhoI/EcoRI from existing miR-E constructs. Lentivirus was produced by transfection of HEK-293FT cells with shRNA constructs and third generation lentiviral packaging vectors (pRSV-Rev, Addgene #12253; pMD2.G, Addgene #12259, Addgene, Cambridge, MA, USA; and pcDNA3.GP4xCTE, kindly provided by Dr.A.Schambach, Hannover Medical School, Hannover, Germany) as described previously.38 HMC-1 cells and ROSA cells were transduced using spin infection (800 × g, 90 minutes at 32°C) in the presence of polybrene (7 μg/mL). GFP+ cells were sorted on a FACSAria (Becton Dickinson Biosciences, San Jose, CA).

Immunocytochemistry (ICC) and immunohistochemistry (IHC)

To study expression of BRD4 in neoplastic MCs, ICC and IHC were performed according to published protocols.39,40 A description of reagents used in this study is provided in the Supplementary Material.

Evaluation of MC proliferation

Primary cells (MNCs, 10 × 104 cells/well) and cell lines (1-2 × 104 cells/well) were cultured in 96-well microtiter plates in RPMI 1640 medium plus 10% FCS in the absence or presence of JQ1 (5-5,000 nM) at 37°C. After 48 hours, 3H-thymidine (0.5 μCi per well) was applied for 16 hours. Cells were then harvested in filter-membranes and bound radioactivity was measured in a ß-counter. In a separate set of experiments, drugs were applied in the absence or presence of either CHO-supernatant containing SCF or rhSCF (200 ng/ml) for 24 hours. In another set of experiments, drug combinations were tested, using JQ1 and other drugs (PKC412, cladribine, 5-azacytidine, decitabine, ATRA). After an initial screen, PKC412 and ATRA were identified as potent drug partners. HMC-1 cells were incubated with suboptimal concentrations of JQ1 and ATRA or JQ1 and PKC412, at fixed ratio of drug-concentrations. Synergism was defined as supra-additive effect that was confirmed by calculating combination index (CI) values by Calcusyn software as reported.24,26

Assessment of apoptosis and cell cycle progression in neoplastic MCs

A detailed description of apoptosis evaluation techniques and cell cycle progression analysis is provided in the Supplementary Materials.

Evaluation of expression of activation-antigens in drug-exposed cells

Recent data suggest that JQ1 induces maturation in AML cells.32,33 To study the effects of JQ1 on MC differentiation, flow cytometry experiments were performed. HMC-1.1, HMC-1.2, ROSAKIT WT, and ROSAKIT D816V cells were incubated in JQ1 (100-5,000 nM) at 37°C for 48 hours. Then, viable cells were examined for expression of CD2 (LFA-2), CD9, CD11b (C3biR), CD54 (ICAM-1), CD63 (LAMP-3), CD71 (transferrin receptor), CD95 (FAS), CD117 (KIT), CD203c (E-NPP3) and FcεR1α by flow cytometry on a FACSCalibur. In addition, cells were examined for morphologic signs of maturation by Wright-Giemsa staining.

Histamine release experiments

Histamine release experiments were performed on ROSAKIT WT cells following a standard protocol.41,42 A description of the histamine release assay is provided in the Supplement.

Quantitative PCR (qPCR)

A detailed description of qPCR experiments is provided in the Supplementary Materials. Primers used in PCR assays are shown in Supplementary Table S4.

Statistical analysis

Differences in growth and apoptosis in drug-exposed cells were determined by appropriate statistical analysis, including ANOVA and the student’s t test. Results were considered to be significantly different when p was <0.05.

Results

Cytoplasmic BRD4 is expressed abundantly in neoplastic MCs in ASM and MCL

In all 26 SM patients tested, neoplastic MCs were found to exhibit nuclear BRD4 (Figure 1A, Supplementary Table S2). In ASM and MCL, neoplastic MCs also expressed substantial amounts of cytoplasmic BRD4 (Figure 1A). By contrast, in most patients with ISM, MCs expressed only little if any cytoplasmic BRD4 (Figure 1A, Supplementary Table S2). We were also able to show that MCs obtained from patients with advanced SM express BRD4 mRNA (Figure 1B). The MC lines HMC-1.1, HMC-1.2, ROSAKIT WT and ROSAKIT D816V also expressed BRD4 at the mRNA and protein level (Figure 1B, Supplementary Figure S1). Finally, we confirmed expression of cytoplasmic BRD4 in primary neoplastic MCs in advanced SM (Supplementary Figure S1). Preincubation of anti-BRD4 antibody with a BRD4-specific blocking peptide (BP) or antibody-omission resulted in a negative stain (Supplementary Figure S1). Neither normal CD34+ progenitor cells nor SCF-dependent cultured (non-neoplastic) MCs expressed substantial amounts of BRD4 (Supplementary Figure S1).

Figure 1. Expression of BRD4 in neoplastic mast cells (MCs).

Figure 1

Open in a new tab

A: Bone marrow (BM) sections obtained from patients with ISM (upper panels), ASM (middle panels) or MCL (lower panels) were stained with antibodies against BRD4 (left panels) or tryptase (right panels) as described in the text. Tryptase was used to detect MCs. Original magnification: × 100. #: patient details are listed in Table S2. B: BRD4 mRNA expression in HMC-1 cells and ROSA cells (upper panel), in normal BM cells (n=10 donors) and in mononuclear BM cells obtained from patients with ISM (n=42) or advanced SM (ASM/MCL) (n=7) (lower panel). qPCR was performed as described in the text. Results are expressed as percent of ABL mRNA and represent the mean±S.D. of 5 independent experiments in cell lines (upper panel) and median values (indicated by horizontal bars) for each group of donors. As assessed by ANOVA and unpaired t test, BRD4 mRNA expression was significantly higher in the ASM/MCL group compared to normal donors or ISM (p<0.05).

Regulation of expression of BRD4 in neoplastic MCs

SCF was found to upregulate BRD4 mRNA expression in ROSAKIT D816V but not in HMC-1 cells (Supplementary Figure S2). To explore underlying signalling-pathways, we applied KIT-targeting drugs and a panel of signal transduction inhibitors. As shown in Supplementary Figures S2 and S3, the KIT-targeting drugs PKC412 and dasatinib dose-dependently suppressed the expression of BRD4 mRNA in all cell lines tested (Supplementary Figure S3). Imatinib was found to suppress BRD4 mRNA expression in HMC-1.1 and ROSAKIT WT, but not in HMC-1.2 or ROSAKIT D816V cells (Supplementary Figure S2). These data are in line with the notion that KIT D816V confers resistance against imatinib.17,18 The MEK inhibitors RDEA119 and PD0325901, the PI3K/mTOR blocker BEZ235 as well as ATRA were also found to downregulate BRD4 expression in HMC-1 and ROSA. Rapamycin induced a slight decrease in BRD4 mRNA expression in HMC-1.2 and ROSAKIT D816V cells, but not in ROSAKIT WT or HMC-1.1 cells. BRD4 mRNA expression remained unchanged after exposure to the other drugs examined, including the STAT5 blockers piceatannol and pimozide, cladribine (2CdA), and the demethylating agents 5-azacytidine and decitabine. INCB018424 (ruxolitinib) slightly reduced the expression of BRD4 mRNA in ROSAKIT D816V cells and HMC-1.2 cells (Supplementary Figure S2).

The BRD4-targeting drug JQ1 inhibits the proliferation of neoplastic MCs

We have recently shown that shRNAs against BRD4 and the BRD4-targeting drug JQ1 inhibit the growth of AML cells.32,33 To demonstrate a role for BRD4 as potential target in neoplastic MCs, we applied BRD4-specific shRNAs. BRD4 knock-down was confirmed by qPCR. As visible in Figure 2A and Supplementary Figure S4A-S4B, the shRNA-induced knock-down of BRD4 resulted in a significant growth inhibition of HMC-1 cells and ROSA cells. The knock-down of BRD4 was also found to decrease MYC mRNA levels in all cell lines (not shown). JQ1 was found to inhibit 3H-thymidine uptake in HMC-1.1 and HMC-1.2 cells as well as in ROSAKIT WT and ROSAKIT D816V cells, with IC50 values of 500-1,000 nM (Figure 2B and 2C). Similar effects were seen with volasertib and BI2536, two other drugs targeting BRD4 (Supplementary Figure S4C). JQ1 also suppressed growth in primary neoplastic MCs obtained from patients with ASM or MCL (Figure 2D). Interestingly, IC50 values obtained with JQ1 in primary cells were lower compared to IC50 values produced with the MC lines tested. Finally, JQ1 was found to induce a G1 cell cycle arrest in all MC lines examined (Supplementary Figure S5).

Figure 2. BRD4 shRNA and JQ1 inhibit the proliferation of neoplastic MCs.

Figure 2

Open in a new tab

A: Effect of shRNA-mediated knock-down of BRD4 on proliferation of HMC-1.1 cells, HMC-1.2 cells, ROSAKIT WT cells and ROSAKIT D816V cells. Cells were transduced with a control shRNA targeting Renilla luciferase (◇-◇) or with 2 different shRNA constructs targeting BRD4, #602 (Inline graphic) and #1817 (◆-◆). GFP+ cells were sorted, mixed with their non-transduced control cells (ratio 1:1) and maintained in culture for 7 days. The percentage of GFP+ cells was measured daily by flow cytometry. Results show the percentage of GFP+ cells in one typical experiment. B-D: Effects of JQ1 on proliferation of HMC-1 cells (B), ROSA cells (C) and primary neoplastic MCs obtained from patients with ASM or MCL (D). Cells were incubated in the absence (Co) or presence of various concentrations of JQ1 at 37°C for 48 hours. Then, 3H-thymidine uptake was measured. Results are expressed as percent of control and represent the mean±S.D. of 3 independent experiments (B,C) or the mean±S.D. of triplicates (D). Asterisk (*) indicates p<0.05 compared to control (Co).

JQ1 induces apoptosis in neoplastic MCs

JQ1 was found to induce dose-dependent apoptosis in HMC-1 and ROSA cells as evidenced by light microscopy, AnnexinV staining and active caspase-3 staining (Figures 3A-3B, Supplementary Figures S6A). The apoptosis-inducing effect of JQ1 was similar in HMC-1.1 cells compared to HMC-1.2 cells (Figures 3A-B, Supplementary Figure S6A) and was also comparable in ROSAKIT WT and ROSAKIT D816V cells (Figures 3A-B, Supplementary Figure S6A). We were also able to confirm the apoptosis-inducing effects of JQ1 on HMC-1 and ROSA in a Tunel assay (Supplementary Figure S6B). Finally, we were able to show that shRNAs against BRD4 induce apoptosis in HMC-1 cells and ROSA cells (not shown).

Figure 3. JQ1 induces apoptosis in neoplastic mast cells.

Figure 3

Open in a new tab

A: HMC-1 cells and ROSA cells were incubated in the absence (Co) or presence of various concentrations of JQ1 at 37°C for 48 hours. Thereafter, the percentage of apoptotic cells was determined by light microscopy. Results show the percent of apoptotic cells and represent the mean±S.D. of 3 independent experiments. B: After incubation in control medium (Co) or JQ1, HMC-1 and ROSA cells were stained with AnnexinV/propidium iodide (PI), and the percentage of apoptotic cells was determined by flow cytometry. Results show the percent of AnnexinV/PI+ cells and represent the mean±S.D. of 3 independent experiments. Asterisk (*): p<0.05 compared to control.

JQ1 downregulates the expression of CD63, CD71 and FcεRI in neoplastic MCs

Recent data suggest that JQ1 can induce maturation in AML cells.32,33 In the present study, we found that JQ1 dose-dependently down-regulates expression of CD63 and CD71 in HMC-1 and ROSA cells (Supplementary Figure S7A) and HMC-1.2 cells. In ROSAKIT WT cells and ROSAKIT D816V cells, JQ1 was also found to suppress the expression of the FcεRI (Supplementary Figure S7B). Moreover, we found that pre-incubation of ROSAKIT WT cells with JQ1 blocks IgE-mediated histamine release (Supplementary Figure S8) and counteracts IgE-mediated up-regulation of CD63 and CD203c (Supplementary Figure S9). Although JQ1 alone failed to up-regulate expression of differentiation antigens on neoplastic MCs, the drug combination ‘JQ1+ATRA’ was found to up-regulate expression of CD11b (C3biR) and CD54 (ICAM-1) in HMC-1 and ROSA (Supplementary Figure S10A). By contrast, when used as single agent, ATRA did not up-regulate CD54 or CD11b in HMC-1 or ROSA cells (not shown). ATRA also failed to modulate expression of CD63 and CD71, and neither JQ1 nor ATRA (as single agents or in combination) produced visible signs of maturation in HMC-1 or ROSA cells (Supplementary Figure S10B).

Effects of JQ1 on expression of MYC and BCL-2-family members in MCs

Recent data suggest that JQ1 modulates the expression of MYC and various BCL-2 family members in leukemic cells.43-45 We found that JQ1 down-regulates the expression of BCL-2-, MCL-1-, and BCL-xL mRNA as well as MYC mRNA levels in HMC-1 and ROSA cells (Supplementary Figure S11). In addition, we found that JQ1 up-regulates BIM mRNA levels in all 4 cell lines tested (Supplementary Figure S11).

JQ1 synergizes with PKC412 and with ATRA in producing growth inhibition in HMC-1 cells and ROSA cells

Since BRD4-targeting drugs may best be applied in combination with other anti-neoplastic drugs in patients with advanced SM, we screened for suitable drug partners of JQ1. A number of candidates, including cladribine (2CdA), 5-azacytidine and decitabine, did not show synergistic effects with JQ1 (not shown). However, we found that JQ1 strongly synergizes with PKC412 and with ATRA in suppressing the growth of HMC-1 and ROSA cells (Supplementary Figure S12A). In addition, JQ1 was found to synergize with PKC412 and with ATRA in inducing apoptosis in HMC-1 cells and ROSA cells (Supplementary Figures S12B-S12C). Synergism was confirmed by calculating CI values (<1) (not shown).

KIT activation confers resistance against JQ1 in ROSAKIT D816V cells

In a final step, we screened for potential resistance mechanisms that could interfere with JQ1 effects. Since KIT has been implicated in MYC activation and upregulates BRD4 expression, we asked whether KIT activation can interfere with JQ1 effects. Indeed, as visible in Figures 4A and 4B, incubation of ROSAKIT D816V cells with SCF blocked their responsiveness against JQ1. Interestingly, however, SCF did not alter responsiveness of HMC-1.1 and HMC-1.2 cells to JQ1 (Supplementary Figure S13A). We also asked whether the combination ‘JQ1+PKC412’ would overcome KIT-mediated resistance. Indeed, this drug combination was found to produce strong synergistic apoptosis-inducing effects in the presence of SCF in ROSAKIT D816V cells (Supplementary Figure S13B).

Figure 4. Effects of stem cell factor (SCF) on responsiveness of neoplastic MCs to JQ1.

Figure 4

Open in a new tab

A, B: ROSAKIT D816V cells were incubated in the absence (◇-◇ in left image; open bars in right image) or presence of rhSCF (200 ng/ml) (◆-◆ in left image; black bars in right image) at 37°C for 24 hours. Thereafter, cells were washed and incubated in control medium (Co) or in various concentrations of JQ1 (5-5,000 nM) for 48 hours. Then, 3H-thymidine uptake (left panel) and the percentage of active Caspase-3 positive cells (right panel) were measured. Results represent the mean±S.D. of 3 independent experiments. Asterisk (*) indicates p<0.05 compared to Co.

Discussion

Bromodomain-containing proteins have recently been identified as key regulators of cell cycle-progression and growth in various neoplastic cells.29-33 One of these regulators appears to be BRD4, an epigenetic reader involved in the regulation of MYC. We have recently shown that BRD4 is a druggable target in AML cells,32,33 and similar observations have been made in other tumor-models.43-45 We here show that BRD4 is abundantly expressed in neoplastic MCs in advanced SM, and that the BRD4-targeting drug JQ1 induces growth inhibition and apoptosis in these cells.

ASM and MCL are incurable malignancies characterized by drug resistance and a poor survival.1-6,10-15 In these patients, neoplastic cells are often resistant against conventional drugs and KIT-targeting TKIs. Therefore, it is important to define new robust targets in these malignancies. We have identified BRD4 as a novel drug target in neoplastic MCs in advanced SM. To the best of our knowledge this is the first report describing a BET bromodomain-containing molecule as a target in neoplastic MCs.

We have recently shown that BRD4 is expressed abundantly in the cytoplasm of leukemic blasts in AML.33 In the present study, we show that BRD4 is expressed abundantly in the cytoplasm and nuclei of neoplastic MCs in almost all patients with advanced SM, whereas in most patients with ISM, MCs expressed only low levels or no detectable BRD4 in their cytoplasm but still expressed BRD4 in their nuclei. HMC-1 and ROSA cells also expressed cytoplasmic and nuclear BRD4. The abundant expression of cytoplasmic BRD4 in MCs in advanced SM may have several explanations. One hypothesis is that cytoplasmic expression of BRD4 is indicative of a higher proliferative potential of neoplastic cells. Alternatively, KIT-independent lesions acquired during disease progression promote cytoplasmic BRD4 expression. Indeed, apart from KIT D816V, several additional molecular lesions and pro-oncogenic signaling-pathways are expressed in neoplastic MCs in advanced SM.46,47 The exact role and biochemical function of cytoplasmic BRD4 in neoplastic MCs remain unknown. However, there is evidence that BRD4 exerts kinase activity and interacts with cytoplasmic antigens, such as SPA-1, in malignant cells.48-50 Whether BRD4 also fulfils these functions in neoplastic MCs remains unknown.

So far, little is known about the mechanisms contributing to expression of BRD4 in neoplastic MCs. In an attempt to define signaling pathways potentially involved in expression of BRD4, we applied various signal transduction inhibitors. The multi-targeted TKIs PKC412 and dasatinib, known to block the kinase-activity of KIT D816V, were found to downregulate expression of BRD4 in HMC-1 cells and ROSA cells. In addition, we found that various MEK inhibitors and the PI3K/mTOR blocker BEZ235 can downregulate expression of BRD4 in neoplastic MCs. Since MEK as well as PI3K are downstream of KIT, these data suggest that KIT D816V contributes to expression of BRD4 in neoplastic MCs. This observation was supported by the observation that SCF promotes the expression of BRD4 in ROSAKIT D816V cells. However, SCF failed to upregulate expression of BRD4 in HMC-1 cells. These observations suggest that expression of BRD4 in MCs depends not only on KIT activation, but also on other factors. An interesting observation was that BRD4 mRNA expression levels are slightly higher in HMC-1.1 than in HMC-1.2 cells. The reason for this phenomenon remains unknown.

We have recently shown that the BRD4-targeting drug JQ1 exerts strong anti-neoplastic effects in drug-resistant AML cells.33,34 In the present study, we were able to show that JQ1 induces growth inhibition and apoptosis in primary neoplastic cells obtained from patients with advanced SM as well as in HMC-1 and ROSA cells. In each cell line tested, effects of JQ1 were dose-dependent, with reasonable IC50 values, and in each case, growth-inhibition was associated with induction of apoptosis.

In AML, JQ1 effects were found to be associated with signs of maturation.32,33 We were therefore interested to learn whether exposure to JQ1 would lead to maturation in neoplastic MCs. However, we were not able to detect a morphologically visible maturation-inducing effect of JQ1 in HMC-1 or ROSA cells. Moreover, we were unable to demonstrate that JQ1 induces upregulation of differentiation-associated antigens in MCs. Rather, JQ1 was found to even downregulate expression of several key surface antigens in HMC-1 and/or ROSA cells, including CD63 and CD71. Moreover, JQ1 was found to downregulate the expression of FcεRI and to suppress IgE-dependent histamine release in ROSA cells. Collectively, these data suggest that JQ1 blocks proliferation as well as activation of neoplastic MCs which may be relevant clinically, as patients with advanced SM not only suffer from organ infiltration but also from the consequences of MC activation and mediator release.2-6

The intriguing effects of JQ1 on growth and survival of neoplastic MCs prompted us to ask for optimal drug partners and synergistic anti-neoplastic effects. Of all drug-partners tested, PKC412 and ATRA were found to synergize with JQ1 in inhibiting growth and survival in HMC-1 and ROSA cells.

In a final step, we asked whether resistance against JQ1 may occur in neoplastic MCs. In these experiments, we found that SCF introduces resistance against JQ1 in ROSAKIT D816V cells but not in HMC-1 cells. We also asked whether the synergistic activity of the drug combinations JQ1+ATRA and JQ1+PKC412 would overcome SCF-mediated resistance. Indeed, the combination JQ1+PKC412 was found to overcome SCF-mediated resistance in ROSA whereas the combination JQ1+ATRA was unable to overcome resistance. This is best explained by the fact that SCF-induced resistance is mediated by activation of KIT, the principle target of PKC412.

In summary, we have shown that BRD4 is a druggable target in neoplastic MCs. Inhibition of BRD4 by JQ1 is a potent approach to eradicate neoplastic MCs and drug effects can be potentiated by addition of PKC412 or ATRA. Whether BET-targeting drugs exert beneficial effects in patients with advanced SM remains to be determined.

Supplementary Material

1

Acknowledgements

We like to thank Daniela Berger and Gabriele Stefanzl for excellent technical assistance, and Günther Hofbauer and Andreas Spittler (both at the Cell Sorting Core Unit of the Medical University of Vienna) for excellent technical support and advice. This study was supported by Austrian Science Fund, SFB grants #F4611, #F4704-B20 and #F4710-B20, and a Research Grant of The Mastocytosis Society (TMS).

Footnotes

Conflicts of Interest

James E. Bradner is a scientific founder of Tensha Therapeutics, which is developing drug-like derivatives of the JQ1 bromodomain inhibitor as cancer therapeutics, through a license from the Dana-Farber Cancer Institute. Hans-Peter Horny has a consultancy with and received honoraria from Novartis. Peter Valent has a consultancy with and received honoraria and research funding from Novartis. The authors declare no other conflict of interest.

References

  • 1.Horny HP, Valent P. Diagnosis of mastocytosis: general histopathological aspects, morphological criteria, and immunohistochemical findings. Leuk Res. 2001;25:543–551. doi: 10.1016/s0145-2126(01)00021-2. [DOI] [PubMed] [Google Scholar]
  • 2.Valent P, Sperr WR, Schwartz LB, Horny HP. Diagnosis and classification of mast cell proliferative disorders: delineation from immunologic diseases and non-mast cell hematopoietic neoplasms. J Allergy Clin Immunol. 2004;114:3–11. doi: 10.1016/j.jaci.2004.02.045. [DOI] [PubMed] [Google Scholar]
  • 3.Horny HP, Sotlar K, Valent P. Mastocytosis: state of the art. Pathobiology. 2007;74:121–132. doi: 10.1159/000101711. [DOI] [PubMed] [Google Scholar]
  • 4.Metcalfe DD. Mast cells and mastocytosis. Blood. 2008;112:946–956. doi: 10.1182/blood-2007-11-078097. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Arock M, Valent P. Pathogenesis, classification and treatment of mastocytosis: state of the art in 2010 and future perspectives. Expert Rev Hematol. 2010;3:497–516. doi: 10.1586/ehm.10.42. [DOI] [PubMed] [Google Scholar]
  • 6.Valent P, Horny HP, Escribano L, Longley BJ, Li CY, Schwartz LB, et al. Diagnostic criteria and classification of mastocytosis: a consensus proposal. Leuk Res. 2001;25:603–625. doi: 10.1016/s0145-2126(01)00038-8. [DOI] [PubMed] [Google Scholar]
  • 7.Valent P, Horny HP, Li CY, Longley JB, Metcalfe DD, Parwaresch RM, et al. Mastocytosis. In: Jaffe ES, Harris NL, Stein H, Vardiman JW, editors. World Health Organization (WHO) Classification of Tumours. IARC Press edn; Lyon, France: 2001. pp. 291–302. [Google Scholar]
  • 8.Horny HP, Akin C, Metcalfe DD, Escribano L, Bennett JM, Valent P, Bain BJ. Mastocytosis (mast cell disease) In: Swerdlow SH, Campo E, Harris NL, Jaffe ES, Pileri SA, Stein H, Thiele J, Vardiman JW, editors. World Health Organization (WHO) Classification of Tumours. IARC Press edn; 2008. pp. 54–63. [Google Scholar]
  • 9.Valent P, Akin C, Escribano L, Födinger M, Hartmann K, Brockow K, et al. Standards and standardization in mastocytosis: consensus statements on diagnostics, treatment recommendations and response criteria. Eur J Clin Invest. 2007;37:435–453. doi: 10.1111/j.1365-2362.2007.01807.x. [DOI] [PubMed] [Google Scholar]
  • 10.Travis WD, Li CY, Hoagland HC, Travis LB, Banks PM. Mast cell leukemia: report of a case and review of the literature. Mayo Clin Proc. 1986;61:957–966. doi: 10.1016/s0025-6196(12)62636-6. [DOI] [PubMed] [Google Scholar]
  • 11.Sperr WR, Escribano L, Jordan JH, Schernthaner GH, Kundi M, Horny HP, et al. Morphologic properties of neoplastic mast cells: delineation of stages of maturation and implication for cytological grading of mastocytosis. Leuk Res. 2001;25:529–536. doi: 10.1016/s0145-2126(01)00041-8. [DOI] [PubMed] [Google Scholar]
  • 12.Valent P, Akin C, Sperr WR, Escribano L, Arock M, Horny HP, et al. Aggressive systemic mastocytosis and related mast cell disorders: current treatment options and proposed response criteria. Leuk Res. 2003;27:635–641. doi: 10.1016/s0145-2126(02)00168-6. [DOI] [PubMed] [Google Scholar]
  • 13.Akin C, Metcalfe DD. Systemic mastocytosis. Annu Rev Med. 2004;55:419–432. doi: 10.1146/annurev.med.55.091902.103822. [DOI] [PubMed] [Google Scholar]
  • 14.Lim KH, Tefferi A, Lasho TL, Finke C, Patnaik M, Butterfield JH, et al. Systemic mastocytosis in 342 consecutive adults: survival studies and prognostic factors. Blood. 2009;113:5727–5736. doi: 10.1182/blood-2009-02-205237. [DOI] [PubMed] [Google Scholar]
  • 15.Valent P, Ghannadan M, Akin C, Krauth MT, Selzer E, Mayerhofer M, et al. On the way to targeted therapy of mast cell neoplasms: identification of molecular targets in neoplastic mast cells and evaluation of arising treatment concepts. Eur J Clin Invest. 2004;34:41–52. doi: 10.1111/j.0960-135X.2004.01369.x. [DOI] [PubMed] [Google Scholar]
  • 16.Georgin-Lavialle S, Lhermitte L, Dubreuil P, Chandesris MO, Hermine O, Damaj G. Mast cell leukemia. Blood. 2013;121:1285–1295. doi: 10.1182/blood-2012-07-442400. [DOI] [PubMed] [Google Scholar]
  • 17.Gotlib J. KIT mutations in mastocytosis and their potential as therapeutic targets. Immunol Allergy Clin North Am. 2006;26:575–592. doi: 10.1016/j.iac.2006.05.003. [DOI] [PubMed] [Google Scholar]
  • 18.Ustun C, DeRemer DL, Akin C. Tyrosine kinase inhibitors in the treatment of systemic mastocytosis. Leuk Res. 2011;35:1143–1152. doi: 10.1016/j.leukres.2011.05.006. [DOI] [PubMed] [Google Scholar]
  • 19.Nagata H, Worobec AS, Oh CK, Chowdhury BA, Tannenbaum S, Suzuki Y, et al. Identification of a point mutation in the catalytic domain of the protooncogene c-kit in peripheral blood mononuclear cells of patients who have mastocytosis with an associated hematologic disorder. Proc Natl Acad Sci (USA) 1995;92:10560–10564. doi: 10.1073/pnas.92.23.10560. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Longley BJ, Tyrrell L, Lu SZ, Ma YS, Langley K, Ding TG, et al. Somatic c-kit activating mutation in urticaria pigmentosa and aggressive mastocytosis: establishment of clonality in a human mast cell neoplasm. Nat Genet. 1996;12:312–314. doi: 10.1038/ng0396-312. [DOI] [PubMed] [Google Scholar]
  • 21.Fritsche-Polanz R, Jordan JH, Feix A, Sperr WR, Sunder-Plassmann G, Valent P, et al. Mutation analysis of C-KIT in patients with myelodysplastic syndromes without mastocytosis and cases of systemic mastocytosis. Br J Haematol. 2001;113:357–364. doi: 10.1046/j.1365-2141.2001.02783.x. [DOI] [PubMed] [Google Scholar]
  • 22.Furitsu T, Tsujimura T, Tono T, Kitayama H, Koshimizu U, Sugahara H, et al. Identification of mutations in the coding sequence of the proto-oncogene c-kit in a human mast cell leukemia cell line causing ligand-independent activation of the c-kit product. J Clin Invest. 1993;92:1736–1744. doi: 10.1172/JCI116761. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23.Mayerhofer M, Gleixner KV, Hoelbl A, Florian S, Hoermann G, Aichberger KJ, et al. Unique effects of KIT D816V in BaF3 cells: induction of cluster formation, histamine synthesis, and early mast cell differentiation antigens. J Immunol. 2008;180:5466–5476. doi: 10.4049/jimmunol.180.8.5466. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Gleixner KV, Mayerhofer M, Aichberger KJ, Derdak S, Sonneck K, Böhm A, et al. The tyrosine kinase-targeting drug PKC412 inhibits in vitro growth of neoplastic human mast cells expressing the D816V-mutated variant of kit: comparison with AMN107, imatinib, and cladribine (2CdA), and evaluation of cooperative drug effects. Blood. 2006;107:752–759. doi: 10.1182/blood-2005-07-3022. [DOI] [PubMed] [Google Scholar]
  • 25.Shah NP, Lee FY, Luo R, Jiang Y, Donker M, Akin C. Dasatinib (BMS-354825) inhibits KITD816V, an imatinib-resistant activating mutation that triggers neoplastic growth in most patients with systemic mastocytosis. Blood. 2006;108:286–291. doi: 10.1182/blood-2005-10-3969. [DOI] [PubMed] [Google Scholar]
  • 26.Gleixner KV, Mayerhofer M, Sonneck K, Gruze A, Samorapoompichit P, Baumgartner C, et al. Synergistic growth-inhibitory effects of two tyrosine kinase inhibitors, dasatinib and PKC412, on neoplastic mast cells expressing the D816V-mutated oncogenic variant of KIT. Haematologica. 2007;92:1451–1459. doi: 10.3324/haematol.11339. [DOI] [PubMed] [Google Scholar]
  • 27.Gotlib J, Berube C, Growney JD, Chen CC, George TI, Williams C, et al. Activity of the tyrosine kinase inhibitor PKC412 in a patient with mast cell leukemia with the D816V KIT mutation. Blood. 2005;106:2865–2870. doi: 10.1182/blood-2005-04-1568. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 28.Gotlib J, DeAngelo DJ, George TI, Corless CL, Linder A, Langford C, et al. KIT inhibitor midostaurin exhibits a high rate of clinically meaningful and durable responses in advanced systemic mastocytosis: report of fully accrued phase II trial. Blood. 2010;116:316. [Google Scholar]
  • 29.Dawson MA, Kouzarides T, Huntly BJ. Targeting epigenetic readers in cancer. N Engl J Med. 2012;367:647–657. doi: 10.1056/NEJMra1112635. [DOI] [PubMed] [Google Scholar]
  • 30.Godley LA, Le Beau MM. The histone code and treatments for acute myeloid leukemia. N Engl J Med. 2012;366:960–961. doi: 10.1056/NEJMcibr1113401. [DOI] [PubMed] [Google Scholar]
  • 31.Belkina AC, Denis GV. BET domain co-regulators in obesity, inflammation and cancer. Nat Rev Cancer. 2012;12:465–477. doi: 10.1038/nrc3256. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32.Zuber J, Shi J, Wang E, Rappaport AR, Herrmann H, Sison EA, et al. RNAi screen identifies Brd4 as a therapeutic target in acute myeloid leukaemia. Nature. 2011;478:524–528. doi: 10.1038/nature10334. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Herrmann H, Blatt K, Shi J, Gleixner KV, Cerny-Reiterer S, Müllauer L, et al. Small-molecule inhibition of BRD4 as a new potent approach to eliminate leukemic stem- and progenitor cells in acute myeloid leukemia AML. Oncotarget. 2012;3:1588–1599. doi: 10.18632/oncotarget.733. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Sotlar K, Escribano L, Landt O, Möhrle S, Herrero S, Torrelo A, et al. One-step detection of c-kit point mutations using peptide nucleic acid-mediated polymerase chain reaction clamping and hybridization probes. Am J Pathol. 2003;162:737–746. doi: 10.1016/S0002-9440(10)63870-9. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Butterfield JH, Weiler D, Dewald G, Gleich GJ. Establishment of an immature mast cell line from a patient with mast cell leukemia. Leuk Res. 1988;12:345–355. doi: 10.1016/0145-2126(88)90050-1. [DOI] [PubMed] [Google Scholar]
  • 36.Akin C, Brockow K, D’Ambrosio C, Kirshenbaum AS, Ma Y, Longley BJ, et al. Effects of tyrosine kinase inhibitor STI571 on human mast cells bearing wild-type or mutated c-kit. Exp Hematol. 2003;31:686–692. doi: 10.1016/s0301-472x(03)00112-7. [DOI] [PubMed] [Google Scholar]
  • 37.Saleh R, Wedeh G, Herrmann H, Bibi S, Cerny-Reiterer S, Sadovnik I, et al. A new human mast cell line expressing a functional IgE receptor converts to factor-independence and tumorigenicity by KIT D816V-transfection. Blood. 2014;124:111–120. doi: 10.1182/blood-2013-10-534685. [DOI] [PubMed] [Google Scholar]
  • 38.Fellmann C, Hoffmann T, Sridhar V, Hopfgartner B, Muhar M, Roth M, et al. An optimized microRNA backbone for effective single-copy RNAi. Cell Rep. 2013;5:1704–1713. doi: 10.1016/j.celrep.2013.11.020. [DOI] [PubMed] [Google Scholar]
  • 39.Baumgartner C, Cerny-Reiterer S, Sonneck K, Mayerhofer M, Gleixner KV, Fritz R, et al. Expression of activated STAT5 in neoplastic mast cells in systemic mastocytosis: subcellular distribution and role of the transforming oncoprotein KIT D816V. Am J Pathol. 2009;175:2416–2429. doi: 10.2353/ajpath.2009.080953. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40.Peter B, Gleixner KV, Cerny-Reiterer S, Herrmann H, Winter V, Hadzijusufovic E, et al. Polo-like kinase-1 as a novel target in neoplastic mast cells: demonstration of growth-inhibitory effects of small interfering RNA and the Polo-like kinase-1 targeting drug BI 2536. Haematologica. 2011;96:672–680. doi: 10.3324/haematol.2010.031328. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Kneidinger M, Schmidt U, Rix U, Gleixner KV, Vales A, Baumgartner C, et al. The effects of dasatinib on IgE receptor-dependent activation and histamine release in human basophils. Blood. 2008;111:3097–3107. doi: 10.1182/blood-2007-08-104372. [DOI] [PubMed] [Google Scholar]
  • 42.Krauth MT, Mirkina I, Herrmann H, Baumgartner C, Kneidinger M, Valent P. Midostaurin (PKC412) inhibits immunoglobulin E-dependent activation and mediator release in human blood basophils and mast cells. Clin Exp Allergy. 2009;39:1711–1720. doi: 10.1111/j.1365-2222.2009.03353.x. [DOI] [PubMed] [Google Scholar]
  • 43.Fiskus W, Sharma S, Qi J, Valenta JA, Schaub LJ, Shah B, et al. Highly active combination of BRD4 antagonist and histone deacetylase inhibitor against human acute myeloid leukemia (AML) cells. Mol Cancer Ther. 2014;13:1142–1154. doi: 10.1158/1535-7163.MCT-13-0770. [DOI] [PubMed] [Google Scholar]
  • 44.Roderick JE, Tesell J, Shultz LD, Brehm MA, Greiner DL, Harris MH, et al. c-Myc inhibition prevents leukemia initiation in mice and impairs the growth of relapsed and induction failure pediatric T-ALL cells. Blood. 2014;123:1040–1050. doi: 10.1182/blood-2013-08-522698. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 45.Ott CJ, Kopp N, Bird L, Paranal RM, Qi J, Bowman T, et al. BET bromodomain inhibition targets both c-Myc and IL7R in high-risk acute lymphoblastic leukemia. Blood. 2012;120:2843–2852. doi: 10.1182/blood-2012-02-413021. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46.Farina A, Hattori M, Qin J, Nakatani Y, Minato N, Ozato K. Bromodomain protein Brd4 binds to GTPase-activating SPA-1, modulating its activity and subcellular localization. Mol Cell Biol. 2004;24:9059–9069. doi: 10.1128/MCB.24.20.9059-9069.2004. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47.Devaiah BN, Lewis BA, Cherman N, Hewitt MC, Albrecht BK, Robey PG, et al. BRD4 is an atypical kinase that phosphorylates serine2 of the RNA polymerase II carboxy-terminal domain. Proc Natl Acad Sci (USA) 2012;109:6927–6932. doi: 10.1073/pnas.1120422109. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48.Gleixner KV, Mayerhofer M, Cerny-Reiterer S, Hörmann G, Rix U, Bennett KL, et al. KIT-D816V-independent oncogenic signaling in neoplastic cells in systemic mastocytosis: role of Lyn and Btk activation and disruption by dasatinib and bosutinib. Blood. 2011;118:1885–1898. doi: 10.1182/blood-2010-06-289959. [DOI] [PubMed] [Google Scholar]
  • 49.Wilson TM, Maric I, Simakova O, Bai Y, Chan EC, Olivares N, et al. Clonal analysis of NRAS activating mutations in KIT-D816V systemic mastocytosis. Haematologica. 2011;96:459–463. doi: 10.3324/haematol.2010.031690. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Schwaab J, Schnittger S, Sotlar K, Walz C, Fabarius A, Pfirrmann M, et al. Comprehensive mutational profiling in advanced systemic mastocytosis. Blood. 2013;122:2460–2466. doi: 10.1182/blood-2013-04-496448. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

1
NIHMS63111-supplement-1.docx (24.9MB, docx)

RESOURCES